• Latest Posts

Agomab bags $114 million in thriving regenerative medicine sector

Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease

The Billion-Euro European Biotech Companies in 2022

Delayed IPOs and Market Drops Batter Biotech Stocks

The 21 European Biotech Companies To Watch in 2021

Argenx Follows up Phase III Success with Giant €785M Global Offering


Argenx’s Rare Disease Treatment Strikes Gold in Phase III

Argenx Raises Whopping €502M in Global Offering

More News! 3 Apr 2019

€21M Series A to Finance Belgian Biotech’s Regenerative Antibodies

Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal

More News! 19 Sep 2018

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies